false
Catalog
Navigating Clinical Trials: Essential Knowledge fo ...
Alopecia Areata Clinical Trials: Tips and Tricks
Alopecia Areata Clinical Trials: Tips and Tricks
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
David Rosemary, Chair of Dermatology at Indiana University, discusses clinical trials for alopecia areata, focusing on endpoints, placebo rates, and inclusion-exclusion criteria. Trials range from Phase 1, assessing safety, to Phase 3, essential for regulatory approval. Key measures include the SALT score to evaluate hair loss. Study design should consider trial duration, placebos, and patient response duration after treatment stops. Inclusion criteria should account for severity, patient history, and comorbidities. The partnership with patients, safety, and understanding individual needs are crucial. The future may involve biomarkers and new treatments, especially JAK inhibitors and potential topicals.
Asset Subtitle
by David Rosmarin, MD, FAAD
Keywords
alopecia areata
clinical trials
SALT score
JAK inhibitors
biomarkers
Legal notice
Copyright © 2025 American Academy of Dermatology. All rights reserved.
Reproduction or republication strictly prohibited without prior written permission.
×
Please select your language
1
English